A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies

References

• Torre BG, Albericio F. The pharmaceutical industry in 2020. An analysis of FDA drug approvals from the perspective of molecules. Molecules. 2021;26:627. PMID: 33504104. doi:10.3390/molecules26030627.
   PubMed Web of Science ®Google Scholar
• Krishnan M, Darling S. Meeting analytical challenges in a brave new world of next generation biotherapeutics. Drug Discovery. 2020;21:31–9.
   Google Scholar
• Rogers RS, Abernathy M, Richardson DD, Rouse JC, Sperry JB, Swann P, Wypych J, Yu C, Zang L, Deshpande R. A view on the importance of “multi-attribute method” for measuring purity of biopharmaceuticals and improving overall control strategy. AAPS J. 2018;20(1):1–8. PMID: 29192343. doi:10.1208/s12248-017-0168-3.
   Web of Science ®Google Scholar
• Jefferis R. Posttranslational modifications and the immunogenicity of biotherapeutics. J Immunol Res. 2016;2016:5358272. PMID: 27191002. doi:10.1155/2016/5358272.
   PubMed Web of Science ®Google Scholar
• Jenkins N, Murphy L, Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals. Mol Biotechnol. 2008;39(2):113–18. PMID: 18327554. doi:10.1007/s12033-008-9049-4.
   PubMed Web of Science ®Google Scholar
• Moritz B, Stracke JO. Assessment of disulfide and hinge modifications in monoclonal antibodies. Electrophoresis. 2017;38(6):769–85. PMID: 27982442. doi:10.1002/elps.201600425.
   PubMed Web of Science ®Google Scholar
• Wang Q, Chung CY, Chough S, Betenbaugh MJ. Antibody glycoengineering strategies in mammalian cells. Biotechnol Bioeng. 2018;115:1378–93. PMID: 29457629. doi:10.1002/bit.26567.
   PubMed Web of Science ®Google Scholar
• Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci. 2007;96:1–26. PMID: 16998873. doi:10.1002/jps.20727.
   PubMed Web of Science ®Google Scholar
• Beyer B, Schuster M, Jungbauer A, Lingg N. Microheterogeneity of recombinant antibodies: analytics and functional impact. Biotechnol J. 2018;13:1700476. PMID: 28862393. doi:10.1002/biot.201700476.
   Web of Science ®Google Scholar
• Hmiel LK, Brorson KA, Boyne MT. Post-translational structural modifications of immunoglobulin G and their effect on biological activity. Anal Bioanal Chem. 2015;407(1):79–94. PMID: 25200070. doi:10.1007/s00216-014-8108-x.
   PubMed Web of Science ®Google Scholar
• Li W, Kerwin JL, Schiel J, Formolo T, Davis D, Mahan A, Benchaar SA. Structural elucidation of post-translational modifications in monoclonal antibodies. State-of-the-art and emerging technologies for therapeutic monoclonal antibody characterization volume 2. Biopharm Character. 2015:119–83. doi:10.1021/bk-2015-1201.
   Google Scholar
• Yan Y, Wei H, Fu Y, Jusuf S, Zeng M, Ludwig R, Krystek SR, Chen G, Tao L, Das TK. Isomerization and oxidation in the complementarity-determining regions of a monoclonal antibody: a study of the modification-structure-function correlations by hydrogen-deuterium exchange mass spectrometry. Anal Chem. 2016;88(4):2041–50. PMID: 26824491. doi:10.1021/acs.analchem.5b02800.
   PubMed Web of Science ®Google Scholar
• Saitoh S. The identification of Critical Quality Attributes (CQAs) for the development of antibody drugs. Yakugaku zasshi. 2018;138(12):1475–81. PMID: 30504661. doi:10.1248/yakushi.18-00020-1.
   PubMed Web of Science ®Google Scholar
• Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156–64. PMID: 30112460. doi:10.1016/j.conctc.2018.08.001.
   PubMed Web of Science ®Google Scholar
• Geigert J. The challenge of CMC regulatory compliance for biopharmaceuticals and other biologics. Springer. 2013. doi:10.1007/978-1-4614-6916-2.
   Google Scholar
• Yan Y, Liu AP, Wang S, Daly TJ, Li N. Ultrasensitive characterization of charge heterogeneity of therapeutic monoclonal antibodies using strong cation exchange chromatography coupled to native mass spectrometry. Anal Chem. 2018;90(21):13013–20. PMID: 30280893. doi:10.1021/acs.analchem.8b03773.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Martinez T, Woodruff B, Goetze A, Bailey R, Pettit D, Balland A. Hydrophobic interaction chromatography of soluble interleukin I receptor type II to reveal chemical degradations resulting in loss of potency. Anal Chem. 2008;80(18):7022–28. PMID: 18707131. doi:10.1021/ac800928z.
   PubMed Web of Science ®Google Scholar
• Fekete S, Veuthey J-L, Beck A, Guillarme D. Hydrophobic interaction chromatography for the characterization of monoclonal antibodies and related products. J Pharm Biomed Anal. 2016;130:3–18. PMID: 27084526. doi:10.1016/j.jpba.2016.04.004.
   PubMed Web of Science ®Google Scholar
• Wang S, Liu AP, Yan Y, Daly TJ, Li N. Characterization of product-related low molecular weight impurities in therapeutic monoclonal antibodies using hydrophilic interaction chromatography coupled with mass spectrometry. J Pharm Biomed Anal. 2018;154:468–75. PMID: 29587227. doi:10.1016/j.jpba.2018.03.034.
   PubMed Web of Science ®Google Scholar
• Kükrer B, Filipe V, van Duijn E, Kasper PT, Vreeken RJ, Heck AJ, Jiskoot W. Mass spectrometric analysis of intact human monoclonal antibody aggregates fractionated by size-exclusion chromatography. Pharm Res. 2010;27(10):2197–204. PMID: 20680668. doi:10.1007/s11095-010-0224-5.
   PubMed Web of Science ®Google Scholar
• Lu C, Liu D, Liu H, Motchnik P. Characterization of monoclonal antibody size variants containing extra light chains. MAbs. 2013;5(1):102–13. PMID: 23255003. doi:10.4161/mabs.22965.
   PubMed Web of Science ®Google Scholar
• Thiagarajan G, Widjaja E, Heo JH, Cheung JK, Wabuyele B, Mou X, Shameem M. Use of Raman and Raman optical activity for the structural characterization of a therapeutic monoclonal antibody formulation subjected to heat stress. J Raman Spectrosc. 2015;46(6):531–36. doi:10.1002/jrs.4679.
   Web of Science ®Google Scholar
• Bondarenko P, Nichols AC, Xiao G, Shi RL, Chan PK, Dillon TM, Garces F, Semin DJ, Ricci MS. Identification of critical chemical modifications and paratope mapping by size exclusion chromatography of stressed antibody-target complexes. MAbs. 2021;13(1):1887629. PMID: 33615991. doi:10.1080/19420862.2021.1887629.
   PubMed Web of Science ®Google Scholar
• Shi RL, Xiao G, Dillon TM, McAuley A, Ricci MS, Bondarenko PV. Identification of critical chemical modifications by size exclusion chromatography of stressed antibody-target complexes with competitive binding. MAbs. 2021;13(1):1887612. PMID: 33616001. doi:10.1080/19420862.2021.1887612.
   PubMed Web of Science ®Google Scholar
• Andersen JT, Dalhus B, Viuff D, Ravn BT, Gunnarsen KS, Plumridge A, Bunting K, Antunes F, Williamson R, Athwal S, et al. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. J Biol Chem. 2014;289:13492–502. PMID: 24652290. doi:10.1074/jbc.M114.549832.
   PubMed Web of Science ®Google Scholar
• Stracke J, Emrich T, Rueger P, Schlothauer T, Kling L, Knaupp A, Hertenberger H, Wolfert A, Spick C, Lau W, et al. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies. MAbs. 2014;6(5):1229–42. PMID: 25517308. doi:10.4161/mabs.29601.
   PubMed Web of Science ®Google Scholar
• Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcγRIIIa. Clin Cancer Res. 2006;12(9):2879–87. PMID: 16675584. doi:10.1158/1078-0432.CCR-05-2619.
   PubMed Web of Science ®Google Scholar
• Niwa R, Hatanaka S, Shoji-Hosaka E, Sakurada M, Kobayashi Y, Uehara A, Yokoi H, Nakamura K, Shitara K. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcγRIIIa functional polymorphism. Clin Cancer Res. 2004;10(18):6248–55. PMID: 15448014. doi:10.1158/1078-0432.CCR-04-0850.
   PubMed Web of Science ®Google Scholar
• Yan Y, Xing T, Wang S, Li N. Versatile, sensitive, and robust native LC–MS platform for intact mass analysis of protein drugs. J Am Soc Mass Spectrom. 2020;31(10):2171–79. PMID: 32865416. doi:10.1021/jasms.0c00277.
   PubMed Web of Science ®Google Scholar